Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Holdings Inc. demonstrates a robust financial outlook, supported by a significant increase in its patient pool eligibility, which has expanded over 24-fold due to a protocol update, positioning the company for substantial growth in enrollment by mid-2026. The company has also experienced a year-over-year rise in research and development expenses, increasing 21% to $14.0 million, indicating a strong commitment to advancing its innovative product candidates. Furthermore, the positive clinical data published regarding AVIM therapy's effectiveness in improving cardiac function highlights the potential market impact and attractiveness of Orchestra BioMed's offerings within the biomedical sector.

Bears say

Orchestra BioMed Holdings Inc. has faced persistent operating losses since its inception, which raises concerns about its potential for achieving consistent profitability in the future. Additionally, the lengthy and costly nature of clinical trials adds further uncertainty, as they may not validate the safety and efficacy of the company's product candidates. Furthermore, the risk of inadequate intellectual property protection could hinder the commercialization efforts of its innovations, exacerbating the challenges the company currently faces.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.